AnaptysBio to Drop Eczema Drug Candidate

AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
Shares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist, was unsuccessful.
AnaptysBio to abandon eczema drug development after mid-stage trial failure
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower.
AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall
AnaptysBio shares plummeted in premarket trading Wednesday after the company said it will discontinue its dermatitis treatment after the drug failed to meet its targets in recent trials. Shares fell over 39% to $14 ahead of the morning bell.
AnaptysBio Stock Under Pressure After Scrapping Eczema Drug Program: Retail Is Devastated
Shares of AnaptysBio Inc. remained flat in premarket trading Thursday after plunging over 32% in the prior session, marking the stock’s steepest single-day loss since March 2021. The collapse followed the company’s announcement that it would halt further investment in its experimental therapy ANB032 after the drug failed to meet primary and secondary endpoints in a Phase 2b trial for moderate-to-severe atopic dermatitis,
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.
GlobalData on MSN9h
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints
AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...
FierceBiotech1d
AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be ...
The Pharma Letter1d
AnaptysBio drops development of ANB032 following trial miss
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...
Seeking Alpha20d
AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
AnaptysBio has been able to use its technology ... and strong activity in reducing pathogenic T-cells. ANB032, their BTLA agonist, is also in Phase 2b trials for atopic dermatitis.
AnaptysBio announces Phase 2b trial of ANB032 did not meet primary endpoint
AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...
Key Takeaways From AnaptysBio Analyst Ratings
Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing ...
ETF Daily News26d
Wedbush Reaffirms “Outperform” Rating for AnaptysBio (NASDAQ:ANAB)
AnaptysBio (NASDAQ:ANAB – Get Free Report ... a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 ...
Yahoo Finance23d
AnaptysBio, Inc. (ANAB)
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis ... 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused ...
AnaptysBio, Inc.: Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in ...